- Home
- SCWO vs MRSN Comparison
SCWO vs MRSN Comparison
Compare SCWO & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCWO
- MRSN
- Stock Information
- Founded
- SCWO 2021
- MRSN 2001
- Country
- SCWO United States
- MRSN United States
- Employees
- SCWO N/A
- MRSN N/A
- Industry
- SCWO Environmental Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SCWO Utilities
- MRSN Health Care
- Exchange
- SCWO Nasdaq
- MRSN Nasdaq
- Market Cap
- SCWO 49.2M
- MRSN 47.1M
- IPO Year
- SCWO N/A
- MRSN 2017
- Fundamental
- Price
- SCWO $0.37
- MRSN $9.44
- Analyst Decision
- SCWO
- MRSN Strong Buy
- Analyst Count
- SCWO 0
- MRSN 3
- Target Price
- SCWO N/A
- MRSN $33.00
- AVG Volume (30 Days)
- SCWO 19.5M
- MRSN 66.4K
- Earning Date
- SCWO 11-12-2025
- MRSN 11-13-2025
- Dividend Yield
- SCWO N/A
- MRSN N/A
- EPS Growth
- SCWO N/A
- MRSN N/A
- EPS
- SCWO N/A
- MRSN N/A
- Revenue
- SCWO $1,231,413.00
- MRSN $34,769,000.00
- Revenue This Year
- SCWO $5,945.19
- MRSN N/A
- Revenue Next Year
- SCWO $106.82
- MRSN N/A
- P/E Ratio
- SCWO N/A
- MRSN N/A
- Revenue Growth
- SCWO 403.17
- MRSN 16.14
- 52 Week Low
- SCWO $0.16
- MRSN $5.21
- 52 Week High
- SCWO $1.68
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- SCWO 46.67
- MRSN 52.34
- Support Level
- SCWO $0.35
- MRSN $9.24
- Resistance Level
- SCWO $0.42
- MRSN $9.87
- Average True Range (ATR)
- SCWO 0.07
- MRSN 0.70
- MACD
- SCWO -0.01
- MRSN -0.17
- Stochastic Oscillator
- SCWO 10.93
- MRSN 28.81
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.